Oculis Holding AG (OCS) shares soared 6.7% in the last trading session to close at $17.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The sudden price rise can be attributed to growing investor optimism surrounding the company’s three product candidates, OCS-01, which is being developed in late-stage studies for treating diabetic macular edema, privosegtor (OCS-05), which is in mid-stage de ...